Revenue for the March quarter rose 11.8% year-on-year to ₹3,443 crore from ₹3,079.4 crore. EBITDA jumped 36.1% to ₹930 crore from ₹683 crore, while EBITDA margin expanded sharply to 27% from 22.2% a year earlier.
Net profit stood at ₹420.8 crore, broadly stable compared with ₹425.1 crore in the year-ago quarter.
Ahead of the earnings announcement, shares of Mankind Pharma closed 1% lower at ₹2,470 on the NSE.
Vice Chairman and Managing Director Rajeev Juneja said the company delivered around 12% revenue growth during the quarter with adjusted EBITDA margin of 27.1%, driven largely by its domestic business.
The company’s India business, excluding Consumer Healthcare, grew around 13% year-on-year, supported by double-digit expansion in chronic therapies. Cardiac business grew 14.7%, while anti-diabetes therapies rose 11.6%, taking the chronic portfolio’s contribution to nearly 40% of domestic sales.
Mankind Pharma also highlighted sequential recovery in key acute therapies including gastro and vitamins, minerals and nutrients (VMN), while its over-the-counter business grew 20%, aided by strong e-commerce demand.
Also Read: BPCL Q4 Results: One-off impairment drags profit, but margins beat estimates
The company said growth in its international business remained muted during the quarter due to geopolitical headwinds.
Its speciality business portfolio under Bharat Serums and Vaccines (BSV) also recorded strong momentum, with key brands such as Foligraf, HMG, Ossopan and Lactare reporting healthy double-digit growth during the quarter.
